Glucose dysregulation and its association with COVID-19 mortality and hospital length of stay.
COVID-19
Hyperglycemia
Hypoglycemia
Length of stay
Mortality
Journal
Diabetes & metabolic syndrome
ISSN: 1878-0334
Titre abrégé: Diabetes Metab Syndr
Pays: Netherlands
ID NLM: 101462250
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
24
12
2021
revised:
09
02
2022
accepted:
21
02
2022
pubmed:
8
3
2022
medline:
1
4
2022
entrez:
7
3
2022
Statut:
ppublish
Résumé
We investigate the impact of blood glucose on mortality and hospital length of stay (HLOS) among COVID-19 patients. Retrospective study of 456 patients with confirmed COVID-19 and glycemic dysregulation in the New York City area. We found that impaired glucose adjusted for other organs systems involved (OR:1.87; 95% CI:1.36-2.57, p < 0.001), increased glucose nadir (OR:34.28; 95% CI:3.97-296.05, p < 0.01) and abnormal blood glucose levels at discharge (OR:5.07; 95% CI:2.31-11.14, p < 0.001) were each significantly associated with increased odds for mortality. New or higher from baseline insulin requirement during hospitalization (OR:0.34; 95% CI:0.15-0.78; p < 0.05) was significantly associated with decreased odds for mortality. Increased glucose peak (B = 0.001, SE=<0.001, p < 0.001), new or higher from baseline insulin requirement during hospitalization (B = 0.11, SE = 0.03, p < 0.001), and increased days to dysglycemia (B = 0.15, SE = 0.04, p < 0.001) were each significantly associated with increased HLOS. Increased glucose nadir (B = -0.67, SE = 0.07, p < 0.001), insulin intravenous drip (B = -0.10, SE = 0.05, p < 0.05), and increased proportion days endocrine system involved (B = -0.25, SE = 0.06, p < 0.001) were each significantly associated with decreased HLOS. Glucose dysregulation adversely affects mortality and HLOS in COVID-19. These data can help clinicians to guide patient treatment and management in COVID-19 patients.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
We investigate the impact of blood glucose on mortality and hospital length of stay (HLOS) among COVID-19 patients.
METHODS
METHODS
Retrospective study of 456 patients with confirmed COVID-19 and glycemic dysregulation in the New York City area.
RESULTS
RESULTS
We found that impaired glucose adjusted for other organs systems involved (OR:1.87; 95% CI:1.36-2.57, p < 0.001), increased glucose nadir (OR:34.28; 95% CI:3.97-296.05, p < 0.01) and abnormal blood glucose levels at discharge (OR:5.07; 95% CI:2.31-11.14, p < 0.001) were each significantly associated with increased odds for mortality. New or higher from baseline insulin requirement during hospitalization (OR:0.34; 95% CI:0.15-0.78; p < 0.05) was significantly associated with decreased odds for mortality. Increased glucose peak (B = 0.001, SE=<0.001, p < 0.001), new or higher from baseline insulin requirement during hospitalization (B = 0.11, SE = 0.03, p < 0.001), and increased days to dysglycemia (B = 0.15, SE = 0.04, p < 0.001) were each significantly associated with increased HLOS. Increased glucose nadir (B = -0.67, SE = 0.07, p < 0.001), insulin intravenous drip (B = -0.10, SE = 0.05, p < 0.05), and increased proportion days endocrine system involved (B = -0.25, SE = 0.06, p < 0.001) were each significantly associated with decreased HLOS.
CONCLUSION
CONCLUSIONS
Glucose dysregulation adversely affects mortality and HLOS in COVID-19. These data can help clinicians to guide patient treatment and management in COVID-19 patients.
Identifiants
pubmed: 35255293
pii: S1871-4021(22)00053-4
doi: 10.1016/j.dsx.2022.102439
pmc: PMC8867960
pii:
doi:
Substances chimiques
Blood Glucose
0
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
102439Informations de copyright
Copyright © 2022 Diabetes India. Published by Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest All authors have no conflicts of interest to report for the manuscript “Glucose Dysregulation and its Association with COVID-19 Mortality and Hospital Length of Stay”.
Références
Diabetes Res Clin Pract. 2020 Aug;166:108283
pubmed: 32592840
Cell Metab. 2020 Jun 2;31(6):1068-1077.e3
pubmed: 32369736
J Clin Med. 2020 Sep 29;9(10):
pubmed: 33003375
BMC Pulm Med. 2021 Mar 20;21(1):96
pubmed: 33743654
Crit Care. 2007;11(2):R31
pubmed: 17331245
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
J Clin Med. 2020 Aug 10;9(8):
pubmed: 32785086
JAMA Netw Open. 2020 Sep 1;3(9):e2019795
pubmed: 32975574
N Engl J Med. 2020 Jun 25;382(26):2534-2543
pubmed: 32459916
JAMA. 2013 Jun 26;309(24):2579-86
pubmed: 23793267
Heart. 2014 Feb;100(4):288-94
pubmed: 24186563
BMJ Open Diabetes Res Care. 2022 Aug;10(4):
pubmed: 36002176
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Diabetes Metab Syndr. 2021 Jan-Feb;15(1):221-227
pubmed: 33450531
Clin Microbiol Infect. 2020 Sep;26(9):1242-1247
pubmed: 32526275
Diabetes Res Clin Pract. 2020 Oct;168:108381
pubmed: 32853687
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
J Allergy Clin Immunol. 2020 Jul;146(1):110-118
pubmed: 32294485
J Healthc Qual. 2019 May/Jun;41(3):146-153
pubmed: 31094947
JAMA. 2020 Apr 28;323(16):1612-1614
pubmed: 32191259
Electron Physician. 2016 Oct 25;8(10):3042-3047
pubmed: 27957301
Crit Care. 2020 Jun 16;24(1):348
pubmed: 32546258
Cell Metab. 2020 Sep 1;32(3):437-446.e5
pubmed: 32697943
J Diabetes. 2020 Dec;12(12):895-908
pubmed: 32671936
Diabetes Care. 2021 Apr;44(4):976-982
pubmed: 33574126
Cell Metab. 2021 Jan 5;33(1):65-77.e2
pubmed: 33248471
J Diabetes. 2021 Mar;13(3):253-260
pubmed: 33216443
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Rev Bras Ter Intensiva. 2017 Jul-Sep;29(3):364-372
pubmed: 29044305
Diabetologia. 2020 Nov;63(11):2486-2487
pubmed: 32632527
Transfus Apher Sci. 2020 Oct;59(5):102875
pubmed: 32694043
Health Aff (Millwood). 2020 Jul;39(7):1253-1262
pubmed: 32437224
Diabetes Care. 2020 Jul;43(7):1408-1415
pubmed: 32430456
Diabetes Care. 2021 Apr;44(4):865-873
pubmed: 33479161
Clin Infect Dis. 2020 Nov 19;71(16):2114-2120
pubmed: 32427279
Ann Med. 2021 Dec;53(1):103-116
pubmed: 33063540
Ann Intern Med. 2020 Nov 17;173(10):855-858
pubmed: 32628537
J Diabetes Sci Technol. 2020 Jul;14(4):813-821
pubmed: 32389027
Crit Care Explor. 2020 Oct 21;2(10):e0254
pubmed: 33134945
J Clin Endocrinol Metab. 2012 Jan;97(1):16-38
pubmed: 22223765
JAMA. 2021 Apr 13;325(14):1469-1470
pubmed: 33595630
Ann Intern Med. 2020 Nov 17;173(10):773-781
pubmed: 32783686
Am J Emerg Med. 2020 Oct;38(10):2074-2080
pubmed: 33142178
JAMA. 2016 Feb 23;315(8):762-74
pubmed: 26903335
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Diabetes Care. 2021 Feb;44(2):578-585
pubmed: 33323475
Bone Joint J. 2019 Jan;101-B(1):104-112
pubmed: 30601054